Agilent chemstation hplc abort drivers#
The ability to treat autoimmune disease’s underlying drivers without suppressing the immune system will be vital in the post-COVID world.Īgilent subject matter experts will provide Octagon guidance and expertise in methods development, including LC-MS/MS approaches, to assist their research. Octagon’s platform enables the identification of the hallmarks of immune dysregulation, allowing the precise treatment of autoimmune conditions without damaging healthy immune functioning. The immune cells that drive autoimmune disease are genetically identical to healthy immune cells but have become pathologically activated in specific ways. Octagon’s mission is to discover and develop better treatments for autoimmune disease. "Isaac and his team have been active members and contributors to our community since they launched Octagon at our LifeLab in 2017, and we look forward to supporting their ongoing progress at LabCentral." We are excited about the potential of their autoimmune-therapeutics platform," said Johannes Fruehauf. "It’s great to see Octagon awarded with Agilent’s 2021 Golden Ticket. The analytical chemistry expertise and instrumentation that Agilent has provided to LabCentral will be critically important as we turn these insights into new medicines, and the vibrant LabCentral community will help to shape our company culture as we grow." "Octagon has identified important new biology related to the underlying causes of autoimmune disease.
"We are thrilled to have won the Agilent Golden Ticket," said Isaac Stoner, president, and chief executive officer of Octagon Therapeutics.
"The passion and ingenuity with which the Octagon team are approaching and advancing their research towards the precise treatment of autoimmune disease without suppressing the immune system has tremendous potential in improving human health." "Agilent is delighted to continue supporting LabCentral in its quest to provide an environment where promising biotech startups such as Octagon can thrive," said Darlene Solomon.